One of the potential uses of recombinant Lactococcus lactis strains is the treatment of metabolic disorders such as diabetes, obesity, and auto-immune disorders such as atherosclerosis and encephalomyelitis. Creative Biolabs is one of the largest live biotherapeutics products (LBP) services suppliers. We have expertise and capabilities in providing high-quality LBP solutions.
Lactococcus lactis has made great progress from its initial discovery and application in dairy fermentation to the application of biotechnology in genetic engineering to produce various recombinant proteins and metabolites that transcend heterologous barriers. Key desirable characteristics of this Gram-positive lactic acid non-colonizing gut bacteria include its generally recognized safe (GRAS) status, probiotic properties, inclusion body and endotoxin-free, surface display and exocrine techniques, and multiple selections of cloning and induced expression vectors. This has made Lactococcus lactis a desirable and promising host on par with other well-established model bacterial or yeast systems.
Fig.1 The Nisin-Controlled Gene Expression (NICE) system in L. lactis. (Frelet-Barrand, 2022)
Engineered strain in glycerol stock
Starting from 4-6 weeks.
Objective: Construction of Lactobacillus lactis strain expressing A enzyme
Result: Verified by SDS-PAGE and WB, the target protein was expressed in the secretion supernatant and lysed cell supernatant of Lactobacillus lactis NZ9000.
Method:
Turnaround time: 6-8 weeks.
Deliverable:
FGF21 is a metabolic regulator that plays an important role in metabolic diseases such as obesity and diabetes. It is also expressed in mice, and the mouse source is highly homologous to human FGF21. In recent years, it has been widely studied as a potential drug target for the treatment of metabolic diseases. Scientists used Lactococcus lactis, a food-grade bacterium, as the host to express FGF21. In the NZ3900/PNZ8149 expression system, the LacF gene replaces the antibiotic resistance gene as the selective marker, which is safe and can reduce the antibiotic resistance crisis. The recombinant FGF21 expressing strain could express the human FGF21 well in the body and ameliorate obesity in Db/Db mice. Furthermore, a prolonged half-life of human FGF21 was achieved through oral gavage of the human FGF21-expressing strain. Therefore, oral human FGF21 may open up a new avenue for the treatment of obesity and related diseases.
Fig.2 Expression of recombinant Human FGF21 by Lactobacillus lactis NZ3900. (Cao, 2020)
As a common inducible host bacterium, Lactococcus lactis has an important role in research and application. Because of its potential in the production of heterologous proteins of therapeutic or technological value, Lactococcus lactis is becoming increasingly popular, among which the nisin-controlled gene expression (NICE) system is the most commonly used. In its combined form, Lactococcus lactis NZ3900/PNZ8149 is a crucial member of the NICE system. Creative Biolabs is a diverse, knowledgeable, and agile team, with a solid leadership universally recognized in the world of LBP. We have specialized in the custom services of LBP development for researchers around the world. If you are interested in our recombinant lactobacillus expression strain construction services, please contact us for more details.
References
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2024 Creative Biolabs. All Rights Reserved.